Histone Deacetylase Inhibitors in Cancer Treatment
Şule Demirkasaoğlu1, Oytun Erbaş1
1ERBAS Institute of Experimental Medicine, Illinois, USA & Gebze, Türkiye
Keywords: Apoptosis, cancer, cancer treatment, HDAC inhibitors, sirtuin.
Abstract
Histone deacetylases (HDACs) are enzymes that play a critical role in regulating biological processes. Histone deacetylase inhibitors can halt the growth of cancer cells and induce apoptosis by preventing the dysregulated activities of these enzymes. Studies conducted on normal tissues, primary tumors, and human cancer cell lines have shown that the loss of acetylated Lys16 (K16-H4) and trimethylated Lys20 (K20-H4) in histone H4 is a common occurrence. These losses occur in the early stages of cancer development and may contribute to tumor invasion and metastasis. This review provides a comprehensive analysis of the roles of HDACs in cancer and the therapeutic potential of HDAC inhibitors.
Cite this article as: Demirkasaoğlu Ş, Erbaş O. Histone Deacetylase Inhibitors in Cancer Treatment. JEB Med Sci 2024;5(4):259-263.